Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

Company Overview - Zevra Therapeutics, Inc. is a commercial-stage company focused on providing therapies for rare diseases, aiming to address unmet medical needs and deliver life-changing therapeutics to affected individuals [3]. Board of Directors Update - Alicia Secor has been appointed to the Board of Directors, bringing over thirty years of experience in the life sciences industry, including leadership roles at Atalanta Therapeutics and Juniper Pharmaceuticals [2]. - Wendy Dixon, PhD, has retired from the Board, effective immediately, after providing strategic counsel during her tenure [2][3]. Leadership Insights - The Chair of the Board, Tamara A. Favorito, expressed confidence that Alicia Secor's expertise will support the company's strategic execution and enhance shareholder value [2]. - CEO Neil F. McFarlane highlighted Alicia's experience in rare diseases as a valuable addition to the team and thanked Wendy for her leadership [3].